Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYRE Trial in Myeloma Cast Nephropathy
NCT01208818Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2011
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide in multiple myeloma (MM) and myeloma cast nephropathy (LCCN) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Prevalence of renal response at 3 months and Prevalence of patients free of dialysis at 3 months. Started Jun 2011; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
multiple myeloma (MM)myeloma cast nephropathy (LCCN)
Beyond the preview
Go deeper on NCT01208818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208818.